brensocatib
brensocatib: 14 clinical trials tracked.
brensocatib evidence translation
What we can confirm
14 tracked trials
What it means
What to watch
Prepared research question
What is verified about brensocatib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Clinical Trials (14)showing 10 most recent
Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - The CEDAR Study
Primary endpoint: Percent Change From Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Week 16
A Phase 1, Double-blind, Randomized, Single-center Study to Assess the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Subjects
Primary endpoint: Number of Participants With High Acceptability to Each Brensocatib Formulation Based on Palatability Assessments Measured by the 9-point Hedonic Scale
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study
Primary endpoint: Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Subjects
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) of Brensocatib
A Phase 1, Open Label, Fixed Sequence Study to Assess the Pharmacokinetics of Brensocatib When Administered Alone and With Multiple Doses of Rifampin (CYP3A Inducer) or Esomeprazole (Proton Pump Inhibitor) in Healthy Subjects
Primary endpoint: Parts 1 and 2: Area Under the Concentration-time (AUC) of Brensocatib in Plasma
An Open-label, Phase 1 Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Brensocatib in Subjects With Normal Hepatic Function and Subjects With Hepatic Impairment
Primary endpoint: Area Under the Concentration Time Curve (AUC)
A Two-part, Phase I, Double-blind, Placebo- and Positive-controlled Crossover Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Subjects
Primary endpoint: Part 1: Number of Participants who Experienced at least one Treatment-Emergent Adverse Event (TEAE) as Assessed by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)
A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Primary endpoint: Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1
A Phase 1, Open-Label, Single Dose Parallel-Group Study of Brensocatib Following a Single Oral Administration in Subjects With or Without Renal Impairment
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC) of Brensocatib